Project Grant R01HL182950
- The National Heart, Lung, and Blood Institute awarded the Regents of the University of Michigan $724,200 on July 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate endothelial cell fate switches and dysfunction driven by fibrotic matrix remodeling. The research uses mouse models and an in vitro human microphysiological system of arteriole and venule-scale microvessels embedded within tunable stromal mimetic matrices to demonstrate how fibrotic physical cues...
- The National Heart, Lung, and Blood Institute awarded the Regents of the University of Michigan $724,971 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate macrophage 12-lipoxygenase signaling as a therapeutic target in heart failure with preserved ejection fraction (HFPEF). The research program establishes 12-lipoxygenase (12-LOX), an enzyme that converts arachidonic acid into bioactive lipid mediators, as a master regulator of HFPEF progression...
- The National Heart, Lung, and Blood Institute awarded the Regents of the University of Michigan $444,775 on June 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the cardiotoxic mechanisms of osimertinib and evaluate therapeutic interventions targeting mitochondrial oxidative stress. The research addresses clinically significant cardiac adverse effects—including reduced left ventricular ejection fraction, heart failure, and arrhythmias—experienced by...
- The National Heart Lung and Blood Institute awarded the Beckman Research Institute of the City of Hope $813,810 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research on nucleotide supplementation as a treatment strategy for ischemic heart disease and myocardial infarction. The project investigates the role of nucleotide balance in cardiomyocyte proliferation and aims to apply these findings for cardiac repair using large animal models....
- The National Heart, Lung, and Blood Institute awarded the Regents of the University of Michigan $1,026,853 on September 12, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to define the molecular basis of thrombospondin-1-induced fibro-fatty diaphragm remodeling as a driver of obesity-associated respiratory dysfunction. The research investigates how diet-induced obesity promotes diaphragm weakness through fibro-adipogenic progenitor cell expansion and extracellular...
- The National Heart, Lung, and Blood Institute awarded the Regents of the University of Michigan $903,185 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837, Project Grant R01HL183614) to develop a Preemie ECMO System addressing respiratory failure in premature infants for whom extracorporeal membrane oxygenation is currently contraindicated. Work is performed at the University of Michigan in Ann Arbor, Michigan, with a period of performance through April 30,...
- The National Heart, Lung, and Blood Institute awarded the University of Southern California $240,206 under the Cardiovascular Diseases Research program (CFDA 93.837) on August 1, 2026, to engineer therapeutically programmed monocytes that adaptively immunomodulate the post-infarction myocardial microenvironment toward cardiac repair and regeneration. The award funds development of smart monocytes using synnotch receptor circuits that detect inflammation and respond by secreting...
- The National Heart, Lung, and Blood Institute awarded Michigan State University (Henry Ford Health+Michigan State University Health Sciences) $466,362 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to elucidate the mechanisms by which mitochondrial calcium overload impairs cellular energy metabolism. The project uses cryo-electron microscopy and computational physiology to investigate how calcium sequestration regulates oxidative metabolism across multiple...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the Regents of the University of Michigan $256,785 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a preliminary metabolomics-genome-wide association study (GWAS) examining the relationship between genetic variants and sepsis severity. Under this two-year project grant (completion date: August 31, 2027), the University of Michigan will leverage...
- The National Heart, Lung, and Blood Institute, part of the Department of Health and Human Services, awarded $1,619,582 to the University of Virginia on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the cardio-splenic axis in acute myocardial infarction and post-MI heart failure. The project examines the immunopathological mechanisms by which plasmacytoid dendritic cells orchestrate post-MI inflammation and cardiac dysfunction. The research team...
The National Heart, Lung, and Blood Institute awarded the Regents of the University of Michigan $759,670 on August 11, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate metabolite-driven epigenetic regulation in cardiac repair following myocardial infarction. The research examines how disruptions in metabolic pathways deplete critical metabolites—including acetyl-CoA and α-ketoglutarate—required for epigenetic and RNA-modifying enzymes. The project systematically investigates how the enzymes ACSS2 and FTO work together to regulate the epigenome and epitranscriptome, testing whether ACSS2-mediated histone acetylation and FTO-mediated mRNA demethylation synergistically enhance mitochondrial function and restore ATP levels to improve cardiac performance after myocardial infarction. The ultimate completion date is May 31, 2030, with place of performance at Ann Arbor, Michigan. This is a Project Grant, a standard NIH assistance type for investigator-initiated research.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $759.7k | 8/11/26 |